Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis

Abstract

French

Background:

Acute kidney injury (AKI) is a potentially fatal complication of Coronavirus Disease-2019 (COVID-19). Binding of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, to its viral receptor, angiotensin converting enzyme 2 (ACE2), results in viral entry and may cause AKI.

Objectives:

We performed a systematic review and meta-analysis of the frequencies of AKI and renal replacement therapy (RRT) in critically ill COVID-19 patients and compared those frequencies with patients who were infected by respiratory viruses that bind or downregulate ACE2 (ACE2-associated viruses) and viruses that do not bind nor downregulate ACE2 (non-ACE2-associated viruses).

Design:

Systematic review and meta-analysis.

Setting:

Observational studies on COVID-19 and other respiratory viral infections reporting AKI and RRT were included. The exclusion criteria were non-English articles, non-peer-reviewed articles, review articles, studies that included patients under the age of 18, studies including fewer than 10 patients, and studies not reporting AKI and RRT rates.

Patients:

Adult COVID-19, Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and influenza patients.

Measurements:

We extracted the following data from the included studies: author, year, study location, age, sex, race, diabetes mellitus, hypertension, chronic kidney disease, shock, vasopressor use, mortality, intensive care unit (ICU) admission, ICU mortality, AKI, and RRT.

Methods:

We systematically searched PubMed and EMBASE for articles reporting AKI or RRT. AKI was defined by authors of included studies. Critical illness was defined by ICU admission. We performed a random effects meta-analysis to calculate pooled estimates for the AKI and RRT rate within each virus group using a random intercept logistic regression model.

Results:

Of 23 655 hospitalized, critically ill COVID-19 patients, AKI frequencies were not significantly different between COVID-19 patients (51%, 95% confidence interval [CI]: 44%-57%) and critically ill patients infected with ACE2-associated (56%, 95% CI: 37%-74%, P = .610) or non-ACE2-associated viruses (63%, 95% CI: 43%-79%, P = .255). Pooled RRT rates were also not significantly different between critically ill, hospitalized patients with COVID-19 (20%, 95% CI: 16%-24%) and ACE2-associated viruses (18%, 95% CI: 8%-33%, P = .747). RRT rates for both COVID-19 and ACE2-associated viruses were significantly different (P < .001 for both) from non-ACE2-associated viruses (49%, 95% CI: 44%-54%). After adjusting for shock or vasopressor use, AKI and RRT rates were not significantly different between groups.

Limitations:

Limitations of this study include the heterogeneity of definitions of AKI that were used across different virus studies. We could not match severity of infection or do propensity matching across studies. Most of the included studies were conducted in retrospective fashion. Last, we did not include non-English publications.

Conclusions:

Our findings suggest that viral ACE2 association does not significantly alter the rates of AKI and RRT among critically ill patients admitted to the ICU. However, the rate of RRT is lower in patients with COVID-19 or ACE2-associated viruses when compared with patients infected with non-ACE2-binding viruses, which might partly be due to the lower frequencies of shock and use of vasopressors in these two virus groups. Prospective studies are necessary to demonstrate whether modulation of the ACE2 axis with Renin-Angiotensin System inhibitors impacts the rates of AKI and whether they are beneficial or harmful in COVID-19 patients.

Keywords

acute kidney injury renal replacement therapy coronavirus disease-2019 COVID-19 angiotensin converting enzyme 2

What was known before

While a small proportion of patients with Coronavirus Disease-2019 (COVID-19) were known to develop acute kidney injury or require renal replacement therapy, the true rates of acute kidney injury and renal replacement therapy in hospitalized, critically ill COVID-19 patients were unknown. Furthermore, the rates of acute kidney injury and renal replacement therapy in hospitalized patients infected with other respiratory viruses that do or do not bind or downregulate angiotensin converting enzyme 2 (ACE2) have been described in isolation but, it remains unclear whether these rates are different than those in COVID-19. The ongoing debate of whether Renin-Angiotensin System (RAS) inhibitors confer protection against or increases susceptibility to COVID-19 infection underscores the dire need to understand whether viral association with ACE2, through binding or downregulation, is correlated with the development of end-organ injury such as AKI.

What this adds

Acute kidney injury occurs to approximately the same degree in critically ill patients, that is, patients admitted to the ICU, regardless of viral association with ACE2. The minimal impact of ACE2 association with rates of acute kidney injury restates the need for and provides a rationale for trials of RAS inhibitors for the therapeutic management of COVID-19.

Introduction

Coronavirus-Disease 2019 (COVID-19) has resulted in over 140 000 000 cases and over 3 000 000 deaths since it was first identified in December 2019.^1-3

Angiotensin converting enzyme 2 (ACE2) is the viral receptor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).^4-6 ACE2 cleaves angiotensin II (Ang II) into the vasodilatory, anti-inflammatory peptide angiotensin 1-7 (Ang [1-7]).^7,8

ACE2 is also the viral receptor for SARS-CoV-1.⁹ The cellular distribution of ACE2, on the vascular endothelium, kidney, heart, and lungs, may explain, in part, the frequent occurrence of acute kidney injury (AKI), acute cardiac injury (ACI), and acute respiratory distress syndrome (ARDS) in COVID-19 patients.^10-13 SARS-CoV-2 binding to ACE2 leads to SARS-CoV-2 entry and downregulation of ACE2 at the cell membrane, similar to SARS-CoV-1.¹⁴ Other respiratory viruses also downregulate ACE2 expression (eg, influenza H1N1, H5N1, H7N9).^15-17

The main proposed mechanisms of AKI in COVID-19 include (1) renal hypoperfusion due to fever, gastrointestinal losses, cardiomyopathy, shock, and use of vasopressors, (2) direct viral injury, (3) sepsis and septic shock-associated acute tubular necrosis, (4) increased inflammation due to increased pro-inflammatory cytokines and cytokine storm, (5) rhabdomyolysis, (6) micro- and macro-vascular thrombosis, and (7) micro-embolism.^18-20

To our knowledge, no studies compare AKI and RRT in COVID-19 with other respiratory viruses that bind to or downregulate ACE2 and those viruses that are not associated with ACE2. This comparison enhances understanding of the role of ACE2 in the pathophysiology of AKI and could inform therapeutic strategies such as targeting of ACE2 with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) to mitigate AKI in COVID-19.

Accordingly, our objectives were to review and perform a meta-analysis of the frequencies of AKI and RRT in critically ill COVID-19 patients and compare those frequencies with critically ill patients who were infected by respiratory viral infections due to viruses that bind or downregulate ACE2 (ACE2-associated viruses) and viruses that do not involve ACE2 (non-ACE2-associated viruses).

Methods

Eligibility Criteria

We searched PubMed/MEDLINE and EMBASE from database inception up until March 25, 2021, for cohort studies, case control studies, and other systematic reviews and meta-analyses that reported the frequency of AKI, acute renal failure (ARF), or RRT in adults (18 years old or greater) infected with COVID-19. Full-text peer-reviewed articles and peer-reviewed articles published ahead of print were included. Letters and commentaries were also included if they provided patient characteristics. Only articles in English were included in the final analysis. Studies with less than 10 patients were excluded as were studies on cohorts of deceased patients and studies that reported only patients on dialysis or kidney transplant recipients. Non-peer-reviewed articles were excluded as were article abstracts, incomplete articles, research posters, conference abstracts, books, theses, and retracted articles.

Search Strategy and Study Selection

We used a broad search strategy to find relevant articles using the following search terms: COVID, COVID-19, 2019-nCov, and SARS-CoV-2. These terms were combined using “AND” with the terms clinical features, clinical characteristics, kidney injury, renal, kidney, creatinine, renal replacement, and dialysis. For ACE2 and non-ACE2 associated viruses, we used similar search terms for kidney injury as above and replaced COVID-19 with these search terms: influenza, H1N1, H5N1, H3N2, H7N9, SARS, SARS-CoV-1, and MERS (see Supplemental Appendix for full search strategy details).

One reviewer (A.C.) screened titles and abstracts to identify reports of hospitalized COVID-19 patients with AKI or RRT. After reading the full texts of publications, studies were included if they reported the frequency of AKI, acute renal failure (ARF), or RRT in adults (18 years old or greater) infected with COVID-19. We similarly reviewed the literature on patients (18 years old or greater) infected with respiratory viruses that are associated with ACE2 through ACE2 binding or downregulation (SARS-CoV-1, influenza H1N1, influenza H7N9) and respiratory viruses that are not associated with ACE2 (e.g., Middle East Respiratory Syndrome Coronavirus [MERS-CoV] and other influenza strains besides H1N1, H7N9).^9,14-17,21 Other studies were identified from the references in review articles and meta-analyses and were included if they met the inclusion criteria.

Data Extraction

One reviewer (A.C.) extracted the studies from the literature in duplicate using a systematic template. We extracted the following data from each included study: author, journal of publication, study type, study location, age, sex, race, diabetes mellitus, hypertension, chronic kidney disease, shock, vasopressor use, intensive care unit (ICU) admission, ICU mortality, overall mortality, AKI, and RRT.AKI in the original publications was defined using a variety of definitions including the Kidney Disease Improving Global Outcomes (KDIGO) criteria, the Acute Kidney Injury Network (AKIN) criteria, the risk of renal failure, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage renal failure (RIFLE) criteria or the presence of elevated serum creatinine.^22-24 Critical illness was defined as admission to the intensive care unit (ICU). Results were not reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist, and a risk of bias assessment was performed on individual studies (Supplemental Table 4).

Statistical Analysis

Results of all included studies were summarized quantitatively. Pooled estimates for the AKI and RRT rate within each virus group and comparison of rates between groups were obtained using random effects (RE) meta-analysis based on a random intercept logistic regression model with logit link and covariate being virus group.^25,26 Pairwise comparisons between virus groups were done by testing the appropriate regression coefficient using Wald-type test from the estimated model. Mixed effects meta-regression was further conducted to adjust for the prevalence of shock and vasopressors use in each study when comparing the virus groups. Among the included studies, only overall prevalence of shock and vasopressors use was reported, but not the ones within critically ill. Since shock is a critical illness and vasopressors are only administered in critically ill patients, we will assume all patients who had shock or used vasopressors are critically ill patients for the purpose of computing these prevalence rates within critically ill. Given that few studies have both shock and vasopressors use data available, we examined these variables as two separate adjusted analyses. Log odds of AKI or RRT was considered as the outcome variable in the regression. Results from the meta-regression were thus expressed as odds ratios. Random effects meta-analysis and mixed effects meta-regression were performed using the meta package in R 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria). Study heterogeneity was assessed visually by funnel plot with a minimum of 10 studies and asymmetry was assessed by the Begg adjusted rank correlation test. Statistical heterogeneity was assessed by I².

Results

Study Selection and Characteristics

After screening 6560 COVID-19 titles and abstracts, 5622 studies were excluded. We assessed 938 full-text articles for their eligibility. Following assessment for eligibility, 867 COVID-19 articles were excluded because they (1) were review articles or meta-analyses, (2) did not report rates of AKI or RRT in critically ill patients, (3) were not written in English, (4) included only patients on dialysis or kidney transplant recipients, or (5) included patients under 18 years of age or did not specify the minimum age of study participants. After reviewing the full texts of 938 articles, 71 COVID-19 studies were included in the meta-analysis (Figure 1A).^1-3,13,27-94 Similarly, 7742 articles on ACE2-associated (SARS-CoV-1, influenza H1N1, H7N9) and non-ACE2-associated viruses (MERS-CoV, other influenza strains) were screened based on their titles and abstracts and 6841 articles were excluded. The full-texts of 901 articles were reviewed and 20 studies on ACE2-associated viruses and 3 studies on non-ACE2-associated viruses were included in the meta-analysis (Figure 1B).^95-117 The majority of the included COVID-19 studies were from the United States (n = 28) and China (n = 17) but other included studies were from England (n = 5), France (n = 4), Brazil (n = 3), South Korea (n = 2), Mexico (n = 2), and Canada, Sweden, Netherlands, Italy, Switzerland, Bahrain, India, United Arab Emirates, and Saudi Arabia (n = 1 each). The last study was conducted jointly in France and Spain.³⁸ Included studies on ACE2-associated and non-ACE2-associated viruses were not predominantly associated with any country and were variable. The characteristics of the included studies are provided in Supplemental Table 1.

Figure 1.

Flow diagrams of the search strategies showing included and excluded studies in the meta-analysis of acute kidney injury (AKI) and renal replacement therapy (RRT) in a) COVID-19 and b) ACE2- and non-ACE2-associated viral infections.

Characteristics of Included Study Populations

Females made up 38% (n = 20 615) of the studied hospitalized COVID-19 population and represented 66% (n = 1082) and 32% (n = 120) of the populations infected with ACE2-associated viruses and non-ACE2-associated viruses, respectively (Supplemental Tables 1a-c). Of the 30 COVID-19 studies that reported race, 24% (n = 12 157) of the included population was Black or African American (Supplemental Table 1a). Similarly, 32% (n = 15 167), 27% (n = 8535), and 5% (n = 1163) of the included population were white, Hispanic or Latino, and Asian, respectively (data not shown). The frequency of hospitalized COVID-19 patients that had diabetes mellitus, hypertension, and chronic kidney disease (CKD) were 35% (n = 18 959), 58% (n = 27 072), and 13% (n = 6054), respectively (Supplemental Table 1a). In hospitalized patients infected with ACE2-associated viruses, 20% (n = 261), 31% (n = 159), and 6% (n = 69) had underlying diabetes mellitus, hypertension, and CKD, respectively (Supplemental Table 1b). Similarly, rates of these underlying comorbidities in hospitalized patients infected with non-ACE2-associated viruses were 50% (n = 170), 50% (n = 6), and 29% (n = 107), respectively (Supplemental Table 1c).

Acute Kidney Injury in COVID-19 and in ACE2-Associated and Non-ACE2-Associated Viruses

Among hospitalized COVID-19 patients (n = 54 173), 44% were critically ill (n = 23 655) (Table 1). In patients hospitalized with ACE2-associated viruses (n = 1575), 94% (n = 1485) were critically ill whereas in hospitalized patients with non-ACE2-associated viruses (n = 370), 100% (n = 370) were critically ill. AKI frequencies did not differ between virus groups in critically ill patients: COVID-19 51% (95% confidence interval [CI]: 44%-57%), ACE2-associated respiratory viruses 56% (95% CI: 37%-74%, P = .610), and non-ACE2-associated viruses 63% (95% CI: 43%-79%, P = .255) or between ACE2-associated respiratory viruses and non-ACE2-associated viruses (P = .624) (Figure 2).

Table 1.

AKI in Cohorts of Hospitalized Adult (≥18 Years Old) COVID-19 Patients.

Publication	Total(n)	ICU admission(n, % of total)	Shock (n, % of total)	Vasopressor use (n, % of total)	RRT (n, % of ICU)	RRT (n, % of total)	AKI (n, % of ICU)	AKI (n, % of total)	DIED + AKI (n, % of AKI)	DIED (n, % of ICU)	DIED (n, % of total)	KDIGO (Y/N)
Aggarwal et al²⁷	32	12 (38)	6 (19)	6 (19)			9 (75)	13 (41)		9 (75)	9 (28)	X
Aggarwal et al²⁸	16	8 (50)	8 (50)	8 (50)			8 (100)	11 (69)		3 (38)	3 (19)
Al Sulaiman²⁹	560	560 (100)		306 (55)	106 (19)	106 (195)	262 (47)	262 (47)		237 (42)	237 (42)
Arentz et al³⁰	21	21 (100)		14 (66)			4 (19)	4 (19)		11 (52)	11 (52)	X
Argenziano et al³¹	850	236 (28)		16 (2)	83 (35)	117 (14)	184 (78)	288 (34)		103 (44)	189 (22)
Auld et al³²	217	217 (100)	143 (66)	143 (66)	63 (29)	63 (29)				62 (29)	62 (29)
Azoulay et al³³	379	379 (100)		165 (44)	73 (19)	73 (19)	193 (51)	193 (51)		97 (26)	100 (26)	X
Bhatraju et al³⁴	24	24 (100)	17 (71)	17 (71)	14 (58)	14 (58)	5 (21)	5 (21)		12 (50)	12 (50)	X
Bowe et al³⁵	5216	1693 (32)				201 (4)	838 (49)	1655 (32)	559 (34)		832 (16)	X
Burke et al³⁶	166	166 (100)			43 (26)	43 (26)	43 (26)	43 (26)	24 (56)	60 (36)	60 (36)
Cao et al³⁷	102	18 (18)	10 (10)		4 (22)	6 (6)	8 (44)	20 (20)	15 (75)	6 (33)	17 (17)
Chaibi et al³⁸	211	211 (100)		155 (73)	41 (19)	41 (19)	55 (26)	55 (26)	38 (69)	69 (33)	69 (33)	X
Chan et al³⁹	3993	976 (24)		993 (25)	238 (24)	347 (9)	745 (76)	1835 (46)	918 (50)	324 (33)	1085 (27)	X
Chand et al⁴⁰	300	300 (100)	233 (78)	233 (78)	133 (44)	133 (44)	230 (77)	230 (77)	138 (60)	157 (52)	157 (52)	X
Charytan et al⁴¹	4732	1056 (22)			213 (20)	237 (5)	788 (75)	1386 (29)	482 (35)	543 (51)	995 (21)
Chaudri et al⁴²	300	80 (27)				3/246 (1)	23/28 (82)	82 (27)	16/28 (57)		39 (13)	X
Cobb et al⁴³	65	65 (100)	5 (8)	5 (8)	7 (11)	7 (11)	28 (43)	28 (43)		26 (40)	26 (40)	X
Costa et al⁴⁴	102	102 (100)		48 (47)	27 (26)	27 (26)	57 (56)	57 (56)	19 (33)	23 (23)	23 (23)	X
Cummings et al⁴⁵	257	257 (100)		170 (66)	79 (31)	79 (31)	80 (31)	80 (31)		101 (39)	101 (39)	X
Doher et al⁴⁶	201	201 (100)	5/29 (17)	82 (41)	34 (17)	34 (17)	101 (50)	101 (50)	24 (24)	26 (13)	29 (14)	X
Dudoignon et al⁴⁷	51	51 (100)			10 (20)	10 (20)	26 (51)	26 (51)	11 (42)	14 (27)	14 (27)	X
Ferguson et al^{48 a}	72	21 (29)		13 (47)	4 (19)	4 (6)	4 (19)	4 (6)		3 (14)	6 (8)	X
Filardo et al⁴⁹	270	135 (50)			55 (41)	56 (21)	99 (74)	123 (46)	65 (53)	72 (53)	78 (29)	X
Fisher et al⁵⁰	3345	438/3341 (13)				164 (5)	382 (87)	1903 (57)			775 (23)	X
Flythe et al⁵¹	4264	4264 (100)	462 (11)	1773 (42)	82/4121 (2)	82/4121 (2)	82/4121 (2)	82/4121 (2)		1598 (37)	1598 (37)
Fominskiy et al⁵²	99	99 (100)			17 (17)	17 (17)	72 (72)	72 (72)	26 (36)	29 (29)	29 (29)	X
Gasparini et al⁵³	372	372 (100)			121 (33)	121 (33)	168 (45)	168 (45)	81 (48)	139 (37)	139 (37)	X
Ghosn et al⁵⁴	110	110 (100)		66 (60)	27 (25)	27 (25)	50 (45)	50 (45)	25 (50)	27 (25)	27 (25)	X
Gupta et al⁵⁵	3099	3099 (100)		1305 (42)	637 (21)	637 (21)	1685 (54)	1685 (54)	403 (24)	1284 (41)	1284 (41)	X
Hamilton et al⁵⁶	1032	165 (16)				32 (3)	73 (44)	210 (20)	110 (52)	59 (36)	326 (32)	X
Hansrivijit et al⁵⁷	283	89 (31)		53 (19)		16 (6)	56 (63)	168 (59)	40 (24)		55 (19)	X
Hong et al⁵⁸	98	13 (13)	9 (9)		3 (23)	3 (3)	8 (62)	9 (9)		4 (31)	5 (5)	X
Huang et al¹	41	13 (32)	3 (7)		3 (23)	3 (7)	3 (23)	3 (7)		5 (38)	6 (15)	X
Isted et al⁵⁹	85	85 (100)		51 (60)	17 (20)	17 (20)	53 (62)	53 (62)		38 (45)	38 (45)	X
Joseph et al⁶⁰	100	100 (100)		51 (51)	13 (13)	13 (13)	81 (81)	81 (81)	28 (35)	29 (29)	29 (29)	X
Kolhe et al⁶¹	1161	96 (8)				23 (2)	64 (67)	304 (26)	184 (61)		419 (36)	X
Larsson et al⁶²	260	260 (100)			59 (23)	59 (23)	59 (23)	59 (23)		60 (23)	60 (23)	X
Lee et al⁶³	1002	274 (27)		261 (26)		59 (6)	183 (67)	294 (29)	118 (40)		172 (17)	X
Li et al⁶⁴	107	107 (100)	38 (36)	38 (36)	20 (19)	20 (19)	48 (45)	48 (45)	40 (83)	51 (48)	51 (48)	X
Lowe et al⁶⁵	81	81 (100)		49 (60)	16 (20)	16 (20)	36 (44)	36 (44)	9 (25)	12 (15)	12 (15)	X
Martínez-Rueda et al⁶⁶	1170	443 (38)		110 (9)		50 (4)	259 (58)	349 (30)	182 (52)		321 (27)	X
Matthias et al⁶⁷	188	29 (15)				11 (6)	23 (79)	41 (22)	11 (27)		19 (10)	X
Mitra et al⁶⁸	117	117 (100)		65 (56)	16 (14)	16 (14)				18 (15)	18 (15)
Mohamed et al⁶⁹	575	173 (30)	148 (26)	148 (26)	77 (45)	89 (15)	105 (61)	161 (28)	80 (50)		80/575 (14)	X
Moledina et al⁷⁰	2600	654 (25)		369 (14)	55 (8)	68 (3)	377 (58)	796 (31)	236 (30)		383 (15)	X
Mukherjee et al⁷¹	137	137 (100)			46 (34)	46 (34)	46 (34)	46 (34)			82 (60)	X
Naar et al⁷²	206	206 (100)			46 (22)	46 (22)	148 (72)	148 (72)	19/46 (41)	19/46 (41)	19/46 (41)	X
Ñamendys-Silva et al⁷³	164	164 (100)		139 (85)	24 (15)	24 (15)				85 (52)	85 (52)
Ng et al⁷⁴	9657	2409 (25)		2075 (21)	589 (24)	638 (7)	2042 (85)	3854 (40)	1997 (52)		2418 (25)	X
Okoh et al⁷⁵	251	82 (33)	59 (24)		52 (63)	52 (21)	52 (63)	52 (21)	46 (88)	70 (85)	97 (39)	X
Paek et al⁷⁶	704	46 (7)				8 (1)	15 (33)	28 (4)	13 (28)		24 (3)	X
Qian et al⁷⁷	37	37 (100)	6 (16)		3 (8)	3 (8)	8 (22)	8 (22)		1 (3)	1 (3)	X
Rubin et al⁷⁸	71	71 (100)		52 (73)	10/57 (18)	10/57 (18)	57 (80)	57 (80)	4/19 (21)	4 (6)	4 (6)	X
Samuel et al⁷⁹	900	307 (34)	204 (23)	204 (23)			193 (63)	315 (35)		239 (78)	367 (41)	X
Sang et al⁸⁰	210	210 (100)			52 (25)	52 (25)	92 (44)	92 (44)	65 (71)	93 (44)	93 (44)	X
Suleyman et al⁸¹	355	141 (40)	64 (18)	64 (18)	24 (17)	25 (7)	98 (70)	159 (45)		57 (40)	72 (20)	X
Taher et al⁸²	73	23 (32)			7 (30)	7 (10)	18 (78)	29 (40)	12 (41)		13 (18)	X
Wang et al²	138	36 (26)	12 (9)	13 (9)	2 (6)	2 (1)	3 (8)	5 (4)		6 (17)	6 (4)	X
Wang et al⁸³	116	19 (16)	2 (2)			5 (4)	7 (37)	12 (10)				X
Wang et al⁸⁴	116	11 (9)				5 (4)	0 (0)	0 (0)		7 (64)	7 (6)	X
Wang et al⁸⁵	45	45 (100)			6 (13)	6 (13)	15 (33)	15 (33)		19 (42)	19 (42)
Wang et al⁸⁶	344	344 (100)	114 (33)		9 (3)	9 (3)	86 (25)	86 (25)	80 (93)	133 (39)	133 (39)	X
Wilbers et al⁸⁷	37	37 (100)			13 (35)	13 (35)	22 (59)	22 (59)	9 (41)	12 (32)	12 (32)	X
Xia et al⁸⁸	81	81 (100)	51 (63)	63 (78)	8 (10)	8 (10)	41 (51)	41 (51)	34 (83)	60 (74)	60 (74)	X
Xu et al⁸⁹	671	671 (100)		147 (22)	86 (13)	86 (13)	263 (39)	263 (39)	189 (72)	362 (54)	362 (54)	X
Xu et al⁹⁰	239	239 (100)			12 (5)	12 (5)	119 (50)	119 (50)	99 (83)	147 (62)	147 (62)	X
Yan et al⁹¹	882	105 (12)	178 (20)			17 (2)	58 (55)	115 (13)	68 (59)		128 (15)	X
Yang et al³	52	52 (100)		18 (35)	9 (17)	9 (17)	15 (29)	15 (29)	12 (80)	32 (62)	32 (62)	X
Yu et al⁹²	226	226 (100)	36 (16)		24 (11)	24 (11)	57 (25)	57 (25)		9 (4)	9 (4)	X
Zamoner et al⁹³	101	52 (51)		47 (47)	24 (46)	25 (25)	40 (77)	51 (50)	33 (65)	34 (65)	37 (37)	X
Zheng et al⁹⁴	34	34 (100)			5 (15)	5 (15)	7 (21)	7 (21)	0 (0)	0 (0)	0 (0)	X
Totals SARS-CoV-2	54173	23655 (44)	1813 (20)	9535 (29)	3441 (18)	4281 (8)	11159 (49)	18669 (35)	6562 (44)	6700 (40)	14227 (26)	—
Totals SARS-CoV-2 (KDIGO)	43257	16850 (39)	1200 (24)	7085 (26)	2801 (22)	3584 (8)	9769 (58)	16618 (38)	6041 (45)	3996 (40)	11064 (26)	—

Note. AKI = acute kidney injury; ICU = intensive care unit; RRT = renal replacement therapy; KDIGO = Kidney Disease Improving Global Outcomes Classification; SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2.

Died or discharged to hospice.

Figure 2.

Forest plots of acute kidney injury (AKI) in critically ill patients with COVID-19 and ACE2- and non-ACE2-associated respiratory viral infections.

Definitions of AKI varied between studies (Supplemental Table 2). After only including studies that defined AKI according to KDIGO criteria (61 studies, n = 43 257), the RE meta-analysis pooled AKI rate among critically ill COVID-19 patients was 52% (95% CI: 46%-58%).

Substantial statistical heterogeneity between studies was observed within each virus type (I² = 98.1%, 83.9%, and 79.9% in critically ill patients for COVID-19, ACE2-associated, and non-ACE2-associated, respectively). The funnel plots (Figure 4) revealed no significant asymmetry (Begg test P > .05), but there seemed to exist some heterogeneity between studies. Four studies reported extreme AKI rate of either 100% or less than 1% (2 COVID-19 studies and 2 studies which examined ACE2-associated viruses).^{28,84,110,112} Sensitivity analysis which excluded these studies did not alter our conclusion for the comparisons between the 3 viruses.

Renal Replacement Therapy in COVID-19 and in ACE2-Associated and Non-ACE2-Associated Viruses

In critically ill patients, there were no significant differences in the pooled RRT rates between COVID-19 (20%, 95% CI: 16%-24%) and ACE2-associated viruses (18%, 95% CI 8%-33%; P = .747). However, both COVID-19 and ACE2-associated viruses were significantly different (P < .001 for both) from non-ACE2-binding viruses (49%, 95% CI: 44%-54%; Figure 3). Substantial statistical heterogeneity between studies was observed within each virus type, except for non-ACE2-associated viruses (I² = 95.4%, 89.6%, 0% in critically ill for COVID-19, ACE2-associated, and non-ACE2-associated, respectively). The funnel plots (Figure 4) revealed one outlying study on ACE2-associated viruses.¹¹² Removal of this study did not alter our conclusion for the comparisons between the 3 groups of viruses.

Figure 3.

Forest plots of renal replacement therapy (RRT) in critically ill patients with COVID-19 and ACE2- and non-ACE2-associated respiratory viral infections.

Figure 4.

Funnel plots of acute kidney injury (AKI) and renal replacement therapy (RRT) in critically ill patients with COVID-19 and ACE2- and non-ACE2-associated respiratory viral infections.

After only including studies that defined AKI according to KDIGO criteria (61 studies, n = 43 257), RRT frequency among critically ill COVID-19 patients was 22% (n = 2801) (Table 1; RE meta-analysis pooled rate: 21% (95% CI: 17%-25%).

Shock and Vasopressors in COVID-19 and Viruses That Are or Are not Associated With ACE2

In critically ill patients, shock occurred in 24% (n = 1813/6621) of COVID-19 patients, whereas vasopressors were used in 26% (n = 9535/17 170) of patients (Table 1). In cohorts of patients infected with ACE2-associated viruses, shock was seen in 25% (n = 76/299), whereas in patients infected with non-ACE2-associated viruses, 78% (n = 267/342) of patients experienced shock (Tables 2D and 3C). Similarly, in cohorts of patients infected with ACE2-associated viruses, vasopressors were initiated in 44% (n = 390/884) whereas 78% (n = 289/370) of patients infected with non-ACE2 associated viruses received vasopressor treatment (Tables 2D and 3C). After adjusting for differences in prevalence of shock or vasopressor use between studies, the AKI and RRT rates were not significantly different between the 3 viruses (Supplemental Table 3). Shock and vasopressor use were, however, both positively associated with AKI (odds ratio [OR]: 1.31, 95% CI: 1.14-1.49 and OR: 1.26, 95% CI: 1.07-1.48, respectively) and RRT use (OR: 1.36, 95% CI: 1.18-1.56 and OR: 1.26, 95% CI: 1.11-1.42, respectively) (Supplemental Table 3).

Table 2.

AKI in Cohorts of Hospitalized Adult (≥18 Years Old) Patients Infected With Respiratory Viruses That Bind and/or Downregulate ACE2.

Publication	Total(n)	ICU admission(n, % of total)	Shock (n, % of total)	Vasopressor use (n, % of total)	RRT (% of ICU)	RRT (n, % of total)	AKI (n, % of ICU)	AKI (n, % of total)	DIED + AKI (n, % of AKI)	DIED (n, % ICU)	DIED (n, % of total)
(A) SARS-CoV-1
Fowler et al^95a	38	38 (100)		14 (37)	2 (5)	2 (5)				13 (34)	13 (34)
Gomersall et al⁹⁶	54	54 (100)			6 (11)	6 (11)				14 (26)	14 (26)
Lew et al⁹⁷	46	46 (100)	3 (7)		9 (20)	9 (20)	9 (20)	9 (20)		24 (52)	24 (52)
Totals SARS-CoV-1	138	138 (100)	3 (7)	14 (37)	17 (12)	17 (12)	9 (20)	9 (20)	n/a	51 (37)	51 (37)
(B) Influenza H1N1
Abdulkader et al⁹⁸	47	47 (100)		22 (47)	8 (17)	8 (17)	25 (53)	25 (53)	9 (36)	9 (19)	9 (19)
Bautista et al⁹⁹	32	32 (100)					17 (53)	17 (53)	6 (35)		7 (22)
Casas-Aparicios et al¹⁰⁰	60	60 (100)			4 (7)	4 (7)	43 (72)	43 (72)	17 (40)	19 (32)	19 (32)
Chaari¹⁰¹	34	34 (100)	4 (12)		0 (0)	0 (0)	11 (32)	11 (32)	7 (64)	11 (21)	11 (21)
Chacko et al¹⁰²	31	31 (100)		18 (58)	6 (19)	6 (19)	11 (35)	11 (35)	4 (36)	6 (19)	6 (19)
Demirjian et al¹⁰³	89	36 (40)			12 (33)	12 (13)	24 (67)	37 (42)	9 (24)	10 (28)	10/36 (28)
Koegelenberg et al¹⁰⁴	19	19 (100)	8 (42)		3 (16)	3 (16)	13 (68)	13 (68)	12 (92)		13 (68)
Nicolay et al¹⁰⁵	76	76 (100)		39 (51)	24 (32)	24 (32)	24 (32)	24 (32)		14 (18)	14 (18)
Nin et al¹⁰⁶	84	84 (100)	37 (44)		20 (24)	20 (24)	43 (51)	43 (51)	30 (70)	46 (55)	46 (55)
Pettilä et al¹⁰⁷	628	628 (100)		208/562 (37)	33 (5)	33 (5)	211 (34)	211 (34)	76 (36)	109 (17)	109 (17)
Samra et al¹⁰⁸	61	61 (100)			2 (3)	2 (3)	16 (26)	16 (26)		50 (77)	50 (77)
Tang et al¹⁰⁹	75	75 (100)	10 (13)				8 (11)	8 (11)		26 (35)	26 (35)
Tignanelli et al¹¹⁰	57	57 (100)		44 (77)	38 (67)	38 (67)	57 (100)	57 (100)	20 (35)	20 (35)	20 (35)
Trimarchi et al¹¹¹	22	22 (100)			4 (18)	4 (18)	14 (64)	14 (64)	10 (71)	12 (55)	12 (55)
Vallejos et al¹¹²	44	44 (100)		35 (80)	44 (100)	44 (100)	44 (100)	44 (100)	36 (82)	36 (82)	36 (82)
Venkata et al¹¹³	66	29 (44)	10 (15)	10 (15)	4 (14)	4 (6)		14 (21)		5 (17)	5 (8)
Totals Influenza H1N1	1425	1335 (94)	69 (25)	376 (43)	202 (16)	202 (15)	561 (43)	588 (41)	236 (45)	373 (29)	393 (29)
(C) Influenza H7N9
Yu et al¹¹⁴	12	12 (100)	4 (33)				7 (58)	7 (58)	5 (71)	6 (50)	6 (50)
Totals Influenza H7N9	12	12 (100)	4 (33)	n/a	n/a	n/a	7 (58)	7 (58)	5 (71)	6 (50)	6 (50)
(D) ACE2-associated virus totals
SARS-CoV-1	138	138 (100)	3 (7)	14 (37)	17 (12)	17 (12)	9 (20)	9 (20)		51 (37)	51 (37)
Influenza H1N1	1425	1335 (94)	69 (25)	376 (43)	202 (16)	202 (15)	561 (43)	588 (41)	236 (45)	373 (29)	393 (29)
Influenza H7N9	12	12 (100)	4 (33)				7 (58)	7 (58)	5 (71)	6 (50)	6 (50)
Totals ACE2 viruses	1575	1485 (94)	76 (23)	390 (42)	219 (16)	219 (11)	577 (42)	604 (41)	241 (45)	430 (30)	450 (30)

Note. AKI = acute kidney injury; ACE2 = angiotensin converting enzyme 2; ICU = intensive care unit; RRT = renal replacement therapy; SARS-CoV-1 = Severe Acute Respiratory Syndrome Coronavirus 1.

Vasopressor and inotrope use reported together.

Table 3.

AKI in Cohorts of Hospitalized Adult (≥18 Years) Patients Infected With Respiratory Viral Infections That Do Not Bind or Downregulate ACE2.

Publication	Total(n)	ICU admission(n, % of total)	Shock (n, % of total)	Vasopressor use (n, % of total)	RRT (n, % of ICU)	RRT (n, % of total)	AKI (n, % of ICU)	AKI (n, % of total)	DIED + AKI (n, % of AKI)	DIED (n, % of ICU)	DIED (n, % of total)
(A) MERS-CoV
Arabi et al¹¹⁵	12	12 (100)	5 (42)	8 (67)	7 (58)	7 (58)	7 (58)	7 (58)		7 (58)	7 (58)
Arabi et al¹¹⁶	330	330 (100)	262 (79)	262 (79)	161 (49)	161 (49)	161 (49)	161 (49)	131 (81)	217 (66)	217 (66)
Totals MERS-CoV	372	342 (100)	267 (78)	270 (79)	168 (49)	168 (49)	168 (49)	168 (49)	131 (81)	224 (65)	224 (65)
(B) Influenza (other than H1N1, H7N9)
Dovč et al¹¹⁷	28	28 (100)		19 (68)	12 (43)	12 (43)	23 (82)	23 (82)	8 (35)	8 (29)	8 (29)
Totals Influenza (not H1N1 or H7N9)	28	28 (100)	n/a	19 (68)	12 (43)	12 (43)	23 (82)	23 (82)	8 (35)	8 (29)	8 (29)
(C) Non-ACE2-associated virus totals
MERS-CoV	372	342 (100)	267 (78)	270 (79)	168 (49)	168 (49)	168 (49)	168 (49)	131 (81)	224 (65)	224 (65)
Influenza (not H1N1 or H7N9)	28	28 (100)		19 (68)	12 (43)	12 (43)	23 (82)	23 (82)	8 (35)	8 (29)	8 (29)
Totals Non ACE2 viruses	370	370 (100)	267 (78)	289 (78)	180 (49)	180 (49)	191 (52)	191 (52)	139 (76)	232 (63)	232 (63)

Note. AKI = acute kidney injury; ACE2 = angiotensin converting enzyme 2; ICU = intensive care unit; RRT = renal replacement therapy; MERS-CoV = Middle East Respiratory Syndrome Coronavirus.

Discussion

Among critically ill patients, there were no differences in frequencies of AKI between COVID-19 patients and patients infected with other respiratory viruses. However, RRT rate was significantly lower in patients with COVID-19 or ACE2-associated viruses when compared with patients infected with non-ACE2 associated viruses. Lower frequencies of shock and use of vasopressors may partially account for lower RRT frequencies in COVID-19 and ACE2 associated viruses, because adjustments for shock and vasopressor use revealed no significant differences in rates of RRT between virus classes. CKD prevalence was similar in COVID-19 (13%) and in patients who had infection with ACE2-associated viruses (6%) but lower than in patients with non-ACE2-associated viruses (29%).

The similar rates of AKI in critically ill patients across viral groups suggests, but does not prove, that downregulation or binding of ACE2 may not be associated with increased rates of AKI. The AKI rates in COVID-19 in critically ill patients may not differ from other viruses because there may be common biological mechanisms by which COVID 19, other ACE2-associated and non-ACE2-associated viruses lead to AKI. Studies of renal structure and function in COVID-19 suggest several mechanisms of AKI. Post-mortem renal tissue of COVID-19 patients with AKI shows viral particles in the kidney and SARS-CoV-2 nucleoprotein antigen accumulation in renal tubules and in one study (n = 3), in all renal compartments.^118-120 However, there is debate on whether these particles are indeed viral particles or other intracellular structures.¹²¹ Indications of diffuse proximal tubule injury, severe acute tubular necrosis, and lymphocyte infiltration have also been found.^118-120 Evidence of renal tropism has also been found in cohorts of SARS, MERS, and influenza H1N1 patients.^122-124 In one large study of patients with COVID-19-associated AKI, the most common cause of AKI was acute tubular necrosis, likely from hemodynamic instability possibly due to volume depletion, sepsis, or nephrotoxic drugs.⁶⁹ Similarly, in another study, acute tubular injury (ATI) was the main post-mortem renal finding in 33 COVID-19 patients who had AKI.¹²⁵ Post-mortem analysis of renal tissues of SARS and influenza H1N1 patients also revealed evidence of ATN.^124,126

It is known that AKI and use of RRT are associated with an increased mortality rate.¹²⁷ Here, we found that the AKI-associated mortality rate was 42% for COVID-19 patients, including those who were not critically ill, which is much less than what was seen in MERS patients (81%). Despite potential common pathophysiological mechanisms, this finding lends support to distinct pathophysiological processes of AKI, even among coronaviruses. The high frequencies of AKI and use of RRT in Middle East Respiratory Syndrome (MERS) may be due to the high renal expression of dipeptidyl peptidase-4, the viral receptor for MERS-CoV.²¹

A few other meta-analyses to date have also directly compared AKI and/or RRT rates among the different coronaviruses.^128,129 In a meta-analysis comparing hospitalized patients infected with different coronaviruses and included studies until June 2020, the rates of AKI were found to be 9.0%, 9.6%, and 42.0% in COVID-19 patients, SARS patients, and MERS patients, respectively.¹²⁸ In addition, urgent start kidney replacement therapy rates were reported to be 3.4% and 35.0% for COVID-19 and MERS patients, respectively. However, the study did not report rates of AKI or RRT in critically ill, or ICU, patients as we have done here.

With respect to mortality, it was found that among patients infected with different coronaviruses including SARS-CoV-2, the COVID-19 AKI mortality rate (78.0%) was lower than in SARS (86.6%) patients but higher than in MERS (68.5%) patients.¹²⁹ Furthermore, another meta-analysis found that 72.3%, 98.9%, and 100% hospitalized patients with AKI who died had COVID-19, SARS, and MERS.¹²⁸ The latter but not the former analysis is consistent with our findings that COVID-19-associated AKI mortality rates are lower than those in SARS or MERS-associated AKI (COVID-19 46%, SARS 90%, MERS 81%). Discrepancies in mortality rates across studies may be due in part to emerging evidence that suggests that AKI in COVID-19 has two distinct clinical phenotypes based on whether AKI presents early or late in patients during the course of illness.¹³⁰ It has been suggested that different mechanisms underlie these phenotypes, each associated with an independent risk of mortality, with AKI-early possibly inciting multiple organ dysfunction whereas AKI-late may be a consequence of multiple organ dysfunction. Furthermore, AKI rates and AKI mortality appear to be much higher in the United States than in China, resulting in heterogeneity in AKI mortality rates among different studies.¹³¹

Variable definitions of AKI over these eras of COVID-19 versus ACE2-associated and non-ACE2-associated viruses may have masked differing rates of AKI across viruses, which may have emerged had one standard definition of AKI been used across all included studies. Earlier and better recognition and resuscitation may also have decreased the risks of AKI in the COVID-19 era compared with the earlier eras of infection by ACE2-associated and non-ACE2 associated viruses. Given the difference in mortality rates between groups (COVID-19 25%, patients infected with ACE2-associated viruses 30%, patients infected with non-ACE2-associated viruses 63%), it is possible that more patients in the non-ACE2 associated groups died before developing AKI, thereby underestimating true AKI rates among these patients.

Shock, such as septic shock due to bacterial sepsis, and use of vasopressors are common precedents and causes of AKI and need for RRT because of shock- and vasopressor-associated induced changes in total renal blood flow and distribution of renal blood flow as well as increased levels of pro-inflammatory cytokines and other mediators of AKI.^132-136 In cohorts of critically ill patients with COVID-19, 84% and 70% of non-survivors had septic shock while 60% and 50% had AKI, respectively, suggesting that sepsis and septic shock contribute to AKI among critically ill COVID-19 patients.^12,86 Septic AKI may also be due to pro-inflammatory cytokines which worsen AKI as well as angiotensin II because it is pro-inflammatory.^132-135 Here, adjusting for shock and vasopressors using meta-regression analysis removed the significant differences in rate of RRT between virus classes suggesting—but not proving—that the lower rates of shock and use of vasopressors explains in part the lower rate of RRT in COVID-19 and ACE2-associated viruses compared with the non-ACE2-associated viruses.

Our study complements and extends a meta-analysis by Silver and colleagues that found similar rates of AKI (46%, 95% CI: 35%-57%) in critically ill COVID-19 patients but included fewer studies (because they only searched up until October 14, 2020, and excluded studies not using KDIGO criteria to define AKI), did not adjust for presence of shock or use of vasopressors, and did not compare rates of AKI and RRT in COVID-19 with those rates in patients infected with viruses that do or do not downregulate ACE2.¹³⁷ Similarly, they found that kidney replacement therapy rates among critically ill COVID-19 patients was 19% (95% CI: 15%-22%).¹³⁷ After including studies that defined AKI using KDIGO criteria, we found that AKI and RRT rates among hospitalized, critically ill COVID-19 patients were 52% and 22%, respectively.

The low prevalence (6%) of pre-existing CKD among cohorts of COVID-19 patients suggests that having CKD may not increase patient susceptibility to SARS-CoV-2 infection (Table 1). Use of ACEi or ARBs are cornerstones of CKD treatment and may have conferred a protective effect on these patients. However, the role of ACEi and ARBs in protecting from COVID-19 is controversial and unproven thus far. It is unclear whether developing AKI associated with COVID-19 alters the risk of developing CKD later in life.¹³⁸

Our result that ACE2 association has a minimal impact on rates of AKI in hospitalized patients provides a rationale for trials of renin-angiotensin system inhibitors for the therapeutic management of COVID-19. Two recent randomized controlled trials of continuing or discontinuing ARBs in hospitalized patients already on ARBs found no difference in mortality between groups. However, we note that the mortality rates in the Brazil trial were very low (2.8% vs 2.7% continuing vs discontinuing ARBs, respectively) and therefore the trial was underpowered for such low rates.^139,140

Our study has limitations which include the variable definitions for AKI used in different eras and in different cohorts. AKIN and RIFLE criteria were used to diagnose AKI in earlier SARS, influenza, and MERS studies whereas KDIGO was used in the majority of COVID-19 studies.^22-24 While there is much overlap in the criteria, they are not identical, so some of the difference in AKI rates may be attributable to the different criteria used. We acknowledge that there is a possibility of overlap in reported cases as has been reported in other COVID-19 studies.¹⁴¹ Another limitation is that we could not match severity of infection or do propensity matching across studies. Other limitations include the high I² value associated with COVID-19 studies (98.1%) and that only one reviewer screened the literature and extracted the data. Last, we did not include non-English publications. The inclusion of many studies from China aided our accurate reflection of AKI frequency in COVID-19.

Conclusions

In conclusion, AKI frequencies were not significantly different between critically ill patients, that is, patients admitted to the ICU, with COVID-19 and other respiratory viral infections. However, the rate of RRT is lower in patients with COVID-19 or ACE2-associated viruses when compared with patients infected with non-ACE2-binding viruses, which might partly be due to the lower frequencies of shock and use of vasopressors in these two virus groups. However, despite being statistically significant, only 3 studies on non-ACE2-associated viruses were included in the meta-analysis and thus, more studies on non-ACE2-associated viruses are necessary to support this finding. Shock and vasopressor use may contribute to AKI and RRT in COVID-19. Lastly, underlying CKD rates were similar in COVID-19 and in patients who had infection with ACE2-associated and non-ACE2-associated viruses. Data from comprehensive prospective registries may elucidate true rates of AKI and RRT in COVID-19.

Supplemental Material

sj-pdf-1-cjk-10.1177_20543581211052185 – Supplemental material for Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis

Supplemental material, sj-pdf-1-cjk-10.1177_20543581211052185 for Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis by A. Cau, M. P. Cheng, Terry Lee, A. Levin, T. C. Lee, D. C. Vinh, F. Lamontagne, J. Singer, K. R. Walley, S. Murthy, D. Patrick, O. Rewa, B. Winston, J. Marshall, J. Boyd and Russell JA in Canadian Journal of Kidney Health and Disease

Footnotes

Authors Note

D. C. Vinh is now affiliated with McGill University Health Centre, Montreal, QC, Canada.

Ethics Approval and Consent to Participate

This work did not involve human subjects.

Consent for Publication

All authors provided consent for publication.

Availability of Data and Materials

Not applicable as original data was not collected for this study.

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock. Dr Russell is an inventor on these patents. Dr Russell was a founder, Director, and shareholder in Cyon Therapeutics Inc and is a shareholder in Molecular You Corp. Dr Russell reports receiving consulting fees in the last 3 years from (1) Asahi Kesai Pharmaceuticals of America (AKPA) (was developing recombinant thrombomodulin in sepsis), (2) SIB Therapeutics LLC (developing a sepsis drug), and (3) Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin). Dr Russell is no longer actively consulting for the following: (4) La Jolla Pharmaceuticals (developing angiotensin II; Dr Russell chaired the DSMB of a trial of angiotensin II from 2015 to 2017) and (5) PAR Pharma (sells prepared bags of vasopressin). Dr Russell reports having received an investigator-initiated grant from Grifols (entitled “Is HBP a mechanism of albumin’s efficacy in human septic shock?”) that was provided to and administered by UBC.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded in part by grants from the Canadian Institutes of Health Research (CIHR).

ORCID iD

A. Cau

Supplemental Material

Supplemental material for this article is available online.

References

Huang

Wang

, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi:10.1016/s0140-6736(20)30183-5.

Wang

, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069. doi:10.1001/jama.2020.1585.

Yang

, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-481. doi:10.1016/S2213-2600(20)30079-5.

Hoffmann

Kleine-Weber

Schroeder

, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e278. doi:10.1016/j.cell.2020.02.052.

Walls

Park

Tortorici

, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281-292.e286. doi:10.1016/j.cell.2020.02.058.

Zhou

Yang

X-L

Wang

X-G

, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273. doi:10.1038/s41586-020-2012-7.

Gomes

ERM

Lara

Almeida

PWM

, et al. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3’,5’-cyclic monophosphate-dependent pathway. Hypertension. 2010;55:153-160. doi:10.1161/HYPERTENSIONAHA.109.143255.

Paz Ocaranza

Riquelme

García

, et al. Counter-regulatory renin–angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17:116-129. doi:10.1038/s41569-019-0244-8.

Moore

Vasilieva

, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454. doi:10.1038/nature02145.

10.

Crackower

Sarao

Oudit

, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828. doi:10.1038/nature00786.

11.

Hamming

Timens

Bulthuis

Lely

Navis

van Goor

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-637. doi:10.1002/path.1570.

12.

Zhou

, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062. doi:10.1016/S0140-6736(20)30566-3.

13.

Shi

Qin

Shen

, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802-810. doi:10.1001/jamacardio.2020.0950.

14.

Kuba

Imai

Rao

, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11:875-879. doi:10.1038/nm1267.

15.

Liu

Yang

Tang

, et al. Downregulation of angiotensin-converting enzyme 2 by the neuraminidase protein of influenza A (H1N1) virus. Virus Res. 2014;185:64-71. doi:10.1016/j.virusres.2014.03.010.

16.

Yang

Zhao

, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014;4:7027. doi:10.1038/srep07027.

17.

Zou

Yan

Shu

, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594. doi:10.1038/ncomms4594.

18.

Cantador

Núñez

Sobrino

, et al. Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients. J Thromb Thrombolysis. 2020;50:543-547. doi:10.1007/s11239-020-02176-7.

19.

McFadyen

Stevens

Peter

The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circul Res. 2020;127:571-587. doi:10.1161/CIRCRESAHA.120.317447.

20.

Ronco

Reis

Husain-Syed

Management of acute kidney injury in patients with COVID-19. Lancet Resp Med. 2020;8:738-742. doi:10.1016/S2213-2600(20)30229-0.

21.

Yin

Wunderink

RG.

MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130-137. doi:10.1111/resp.13196.

22.

Bellomo

Ronco

Kellum

Mehta

Palevsky

, Acute Dialysis Quality Initiative Workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212. doi:10.1186/cc2872.

23.

Khwaja

KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179-c184.

24.

Mehta

Kellum

Shah

, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi:10.1186/cc5713.

25.

Schwarzer

Chemaitelly

Abu-Raddad

Rücker

Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. Res Synth Methods. 2019;10(3):476-483. doi:10.1002/jrsm.1348.

26.

Stijnen

Hamza

Ozdemir

Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29:3046-3067. doi:10.1002/sim.4040.

27.

Aggarwal

Shrivastava

Kumar

Ali

Clinical and epidemiological features of SARS-CoV-2 patients in SARI ward of a tertiary care centre in New Delhi. J Assoc Physicians India. 2020;68(7):19-26.

28.

Aggarwal

Garcia-Telles

Aggarwal

, et al. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States. Diagnosis. 2020;7:91-96. doi:10.1515/dx-2020-0046.

29.

Al Sulaiman

Aljuhani

Eljaaly

, et al. Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): a multicenter cohort study. Int J Infect Dis. 2021;105:180-187. doi:10.1016/j.ijid.2021.02.037.

30.

Arentz

Yim

Klaff

, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612-1614.

31.

Argenziano

Bruce

Slater

, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020;369:m1996. doi:10.1136/bmj.m1996.

32.

Auld

Caridi-Scheible

Blum

, et al. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020;48(9):e799-e804. doi:10.1097/CCM.0000000000004457.

33.

Azoulay

Fartoukh

Darmon

, et al. Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset. Intensive Care Med. 2020;46(9):1714-1722. doi:10.1007/s00134-020-06202-3.

34.

Bhatraju

Ghassemieh

Nichols

, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382(21):2012-2022.

35.

Bowe

Cai

Xie

Gibson

Maddukuri

Al-Aly

Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin J Am Soc Nephrol. 2021;16(1):14-25. doi:10.2215/CJN.09610620.

36.

Burke

Haber

Pike

Sonti

Outcomes of renal replacement therapy in the critically ill with COVID-19. Med Intensiva. 2021;45:325-331. doi:10.1016/j.medin.2021.02.004.

37.

Cao

W-J

Cheng

, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):748-755.

38.

Chaibi

Dao

Pham

, et al. Severe acute kidney injury in patients with COVID-19 and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;202(9):1299-1301. doi:10.1164/rccm.202005-1524LE.

39.

Chan

Chaudhary

Saha

, et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol. 2021;32(1):151-160. doi:10.1681/ASN.2020050615.

40.

Chand

Kapoor

Orsi

, et al. COVID-19-associated critical illness—report of the first 300 patients admitted to intensive care units at a New York City Medical Center. J Intensive Care Med. 2020;35(10):963-970. doi:10.1177/0885066620946692.

41.

Charytan

Parnia

Khatri

, et al. Decreasing incidence of acute kidney injury in patients with COVID-19 critical illness in New York City. Kidney Int Rep. 2021;6(4):916-927. doi:10.1016/j.ekir.2021.01.036.

42.

Chaudhri

Moffitt

Taub

, et al. Association of proteinuria and hematuria with acute kidney injury and mortality in hospitalized patients with COVID-19. Kidney Blood Press Res. 2020;45(6):1018-1032. doi:10.1159/000511946.

43.

Cobb

Sathe

Duan

, et al. Comparison of clinical features and outcomes in critically ill patients hospitalized with COVID-19 versus influenza. Ann Am Thorac Soc. 2021;18(4):632-640. doi:10.1513/AnnalsATS.202007-805OC.

44.

Costa

RLD

Sória

Salles

, et al. Acute kidney injury in patients with Covid-19 in a Brazilian ICU: incidence, predictors and in-hospital mortality. J Bras Nefrol. 2021;43(3):349-358.

45.

Cummings

Baldwin

Abrams

, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet (London, England). 2020;395(10239):1763-1770. doi:10.1016/S0140-6736(20)31189-2.

46.

Doher

Torres

Carvalho

Scherer

, et al. Acute kidney injury and renal replacement therapy in critically ill COVID-19 patients: risk factors and outcomes: a single-center experience in Brazil. Blood Purif. 2021;50:520-530. doi:10.1159/000513425.

47.

Dudoignon

Moreno

Deniau

, et al. Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19. Anaesth Crit Care Pain Med. 2020;39(4):453-455.

48.

Ferguson

Rosser

Quintero

, et al. Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, Northern California, USA, March-April 2020. Emerg Infect Dis. 2020;26(8):1679-1685. doi:10.3201/eid2608.201776.

49.

Filardo

Khan

Krawczyk

, et al. Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). PLoS ONE. 2020;15(11):e0242760. doi:10.1371/journal.pone.0242760.

50.

Fisher

Neugarten

Bellin

, et al. AKI in hospitalized patients with and without COVID-19: a comparison study. J Am Soc Nephrol. 2020;31(9):2145-2157. doi:10.1681/ASN.2020040509.

51.

Flythe

Assimon

Tugman

, et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77(2):190-203. doi:10.1053/j.ajkd.2020.09.003.

52.

Fominskiy

Scandroglio

Monti

, et al. Prevalence, characteristics, risk factors, and outcomes of invasively ventilated COVID-19 patients with acute kidney injury and renal replacement therapy. Blood Purif. 2021;50(1):102-109. doi:10.1159/000508657.

53.

Gasparini

Khan

Patel

, et al. Renal impairment and its impact on clinical outcomes in patients who are critically ill with COVID-19: a multicentre observational study. Anaesthesia. 2021;76(3):320-326. doi:10.1111/anae.15293.

54.

Ghosn

Attallah

Badr

, et al. Severe acute kidney injury in critically ill patients with COVID-19 admitted to ICU: incidence, risk factors, and outcomes. J Clin Med. 2021;10(6):1217. doi:10.3390/jcm10061217.

55.

Gupta

Coca

Chan

, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J Am Soc Nephrol. 2021;32(1):161-176. doi:10.1681/ASN.2020060897.

56.

Hamilton

Hanumapura

Castelino

, et al. Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19. PLoS ONE. 2020;15(11):e0241544. doi:10.1371/journal.pone.0241544.

57.

Hansrivijit

Gadhiya

Gangireddy

Goldman

JD.

Risk factors, clinical characteristics, and prognosis of acute kidney injury in hospitalized COVID-19 patients: a retrospective cohort study. Medicines (Basel, Switzerland). 2021;8(1):4. doi:10.3390/medicines8010004.

58.

Hong

Lee

Chung

, et al. Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J. 2020;61:431-437.

59.

Isted

McDonnell

Jones

Grundy

Jeyabraba

Ali

et al. Clinical characteristics and outcomes of 85 intensive care patients with Covid-19 in South London: A single centre observational study. J Intensive Care Soc. 2020;175114372097154. doi:10.1177/1751143720971541

60.

Joseph

Zafrani

Mabrouki

Azoulay

Darmon

Acute kidney injury in patients with SARS-CoV-2 infection. Ann Intens Care. 2020;10(1):117-117. doi:10.1186/s13613-020-00734-z.

61.

Kolhe

Fluck

Selby

Taal

MW.

Acute kidney injury associated with COVID-19: a retrospective cohort study. PLoS Med. 2020;17(10):e1003406. doi:10.1371/journal.pmed.1003406.

62.

Larsson

Brattström

Agvald-Öhman

, et al. Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary hospital in Stockholm, Sweden. Acta Anaesthesiol Scand. 2021;65(1):76-81. doi:10.1111/aas.13694.

63.

Lee

Silberzweig

Akchurin

, et al. Characteristics of acute kidney injury in hospitalized COVID-19 patients in an urban academic medical center. Clin J Am Soc Nephrol. 2021;16(2):284-286. doi:10.2215/CJN.07440520.

64.

Zhang

, et al. Acute kidney injury can predict in-hospital mortality in elderly patients with COVID-19 in the ICU: a single-center study. Clin Interv Aging. 2020;15:2095-2107. doi:10.2147/CIA.S273720.

65.

Lowe

Ferrari

Nasim-Mohi

, et al. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. BMC Nephrol. 2021;22(1):92. doi:10.1186/s12882-021-02296-z.

66.

Martínez-Rueda

Álvarez

Méndez-Pérez

, et al. Community- and hospital-acquired acute kidney injury in COVID-19: different phenotypes and dismal prognosis. Blood Purif. 2021;50(6):931-941. doi:10.1159/000513948.

67.

Diebold

Schaub

Landmann

Steiger

Dickenmann

Acute kidney injury in patients with COVID-19: a retrospective cohort study from Switzerland. Swiss Med Wkly. 2021;151:w20482.

68.

Mitra

Fergusson

Lloyd-Smith

, et al. Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series. CMAJ. 2020;192(26):E694-E701.

69.

Mohamed

Lukitsch

Torres-Ortiz

, et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney360. 2020;1:614-622.

70.

Moledina

Simonov

Yamamoto

, et al. The association of COVID-19 with acute kidney injury independent of severity of illness: a multicenter cohort study. Am J Kidney Dis. 2021;77(4):490-499. doi:10.1053/j.ajkd.2020.12.007.

71.

Mukherjee

Toth

Fenianos

, et al. Clinical outcomes in critically ill coronavirus disease 2019 patients: a unique New York City public hospital experience. Crit Care Explor. 2020;2(8):e0188. doi:10.1097/CCE.0000000000000188.

72.

Naar

Langeveld

El Moheb

, et al. Acute kidney injury in critically-ill patients with COVID-19: a single-center experience of 206 consecutive patients. Ann Surg. 2020;272(4):e280-e281.

73.

Ñamendys-Silva

Alvarado-Ávila

Domínguez-Cherit

, et al. Outcomes of patients with COVID-19 in the intensive care unit in Mexico: a multicenter observational study. Heart Lung. 2021;50(1):28-32. doi:10.1016/j.hrtlng.2020.10.013.

74.

Hirsch

Hazzan

, et al. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis. 2021;77(2):204-215.e1. doi:10.1053/j.ajkd.2020.09.002.

75.

Okoh

Sossou

Dangayach

, et al. Coronavirus disease 19 in minority populations of Newark, New Jersey. Int J Equity Health. 2020;19:93.

76.

Paek

Kim

Park

, et al. Severe acute kidney injury in COVID-19 patients is associated with in-hospital mortality. PLoS ONE. 2020;15(12):e0243528. doi:10.1371/journal.pone.0243528.

77.

Qian

S-Z

Hong

W-D

Lingjie

Chenfeng

Zhendong

Pan

J-Y.

Clinical characteristics and outcomes of severe and critical patients with 2019 novel coronavirus disease (COVID-19) in Wenzhou: a retrospective study. Front Med (Lausanne). 2020;7:552002. doi:10.3389/fmed.2020.552002.

78.

Rubin

Orieux

Prevel

, et al. Characterization of acute kidney injury in critically ill patients with severe coronavirus disease 2019. Clin Kidney J. 2020;13(3):354-361. doi:10.1093/ckj/sfaa099.

79.

Samuel

Mechineni

Aronow

Ismail

Manickam

A review of the characteristics and outcomes of 900 COVID-19 patients hospitalized at a Tertiary Care Medical Center in New Jersey, USA. Arch Med Sci Atheroscler Dis. 2020;5:e306-e312. doi:10.5114/amsad.2020.103039.

80.

Sang

Chen

Zheng

, et al. The incidence, risk factors and prognosis of acute kidney injury in severe and critically ill patients with COVID-19 in mainland China: a retrospective study. BMC Pulm Med. 2020;20(1):290.

81.

Suleyman

Fadel

Malette

, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Netw Open. 2020;3:e2012270.

82.

Taher

Alalwan

Naser

Alsegai

Alaradi

Acute kidney injury in COVID-19 pneumonia: a single-center experience in Bahrain. Cureus. 2020;12(8):e9693. doi:10.7759/cureus.9693.

83.

Wang

Zhu

, et al. Identify the risk factors of COVID-19-related acute kidney injury: a single-center, retrospective cohort study. Front Med (Lausanne). 2020;7:436. doi:10.3389/fmed.2020.00436.

84.

Wang

Chen

, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51:343-348.

85.

Wang

Tan

, et al. Extra-pulmonary complications of 45 critically ill patients with COVID-19 in Yichang, Hubei province, China: a single-centered, retrospective, observation study. Medicine. 2021;100(9):e24604. doi:10.1097/MD.0000000000024604.

86.

Wang

Chen

, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med. 2020;201:1430-1434.

87.

Wilbers

Koning

MV.

Renal replacement therapy in critically ill patients with COVID-19: a retrospective study investigating mortality, renal recovery and filter lifetime. J Crit Care. 2020;60:103-105. doi:10.1016/j.jcrc.2020.07.025.

88.

Xia

Wen

Duan

, et al. Clinicopathological features and outcomes of acute kidney injury in critically ill COVID-19 with prolonged disease course: a retrospective cohort. J Am Soc Nephrol. 2020;31(9):2205-2221. doi:10.1681/ASN.2020040426.

89.

Yang

, et al. Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care. 2020;24(1):394.

90.

Xie

Tong

Qiu

Bagshaw

SM.

Clinical characteristics and outcomes of patients with severe COVID-19 induced acute kidney injury. J Intensive Care Med. 2020;36(3):319-326. doi:10.1177/0885066620970858.

91.

Yan

Zuo

Cheng

, et al. Acute kidney injury is associated with in-hospital mortality in older patients with COVID-19. J Gerontol A Biol Sci Med Sci. 2021;76(3):456-462. doi:10.1093/gerona/glaa181.

92.

, et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. Crit Care. 2020;24:219. doi:10.1186/s13054-020-02939-x.

93.

Zamoner

Santos

CADS

Magalhães

de Oliveira

PGS

Balbi

Ponce

Acute kidney injury in COVID-19: 90 days of the pandemic in a Brazilian public hospital. Front Med (Lausanne). 2021;8:622577. doi:10.3389/fmed.2021.622577.

94.

Zheng

Sun

L-J

, et al. Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China. J Zhejiang Univ Sci B. 2020;21(5):378-387.

95.

Fowler

Lapinsky

Hallett

, et al. Critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290:367-373.

96.

Gomersall

Joynt

Lam

, et al. Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intens Care Med. 2004;30:381-387.

97.

Lew

TWK

Kwek

T-K

Tai

, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290:374-380.

98.

Abdulkader

de Sousa Santos

Caires

Arantes

Andrade

Characteristics of acute kidney injury in patients infected with the 2009 influenza A (H1N1) virus. Clin J Am Soc Nephrol. 2010;5(11):1916-1921.

99.

Bautista

Arcos

Jimenez-Alvarez

, et al. Angiogenic and inflammatory markers in acute respiratory distress syndrome and renal injury associated to A/H1N1 virus infection. Exp Mol Pathol. 2013;94(3):486-492.

100.

Casas-Aparicio

León-Rodríguez

Hernández-Zenteno

, et al. Aggressive fluid accumulation is associated with acute kidney injury and mortality in a cohort of patients with severe pneumonia caused by influenza A H1N1 virus. PLoS ONE. 2018;13:e0192592. doi:10.1371/journal.pone.0192592.

101.

Chaari

Dammak

Chtara

Bahloul

Bouaziz

Acute kidney injury in critically ill A(H1N1)-infected patients: a study of the prognoses. J Ren Care. 2011;37:128-133.

102.

Chacko

Gagan

Ashok

Radha

Hemanth

HV.

Critically ill patients with 2009 H1N1 infection in an Indian ICU. Indian J Crit Care Med. 2010;14:77-82.

103.

Demirjian

Raina

Bhimraj

, et al. 2009 influenza A infection and acute kidney injury: incidence, risk factors, and complications. Am J Nephrol. 2011;34(1):1-8. doi:10.1159/000328386.

104.

Koegelenberg

CFN

Irusen

Cooper

, et al. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. QJM. 2010;103:319-325.

105.

Nicolay

Callaghan

Domegan

, et al. Epidemiology, clinical characteristics and resource implications of pandemic (H1N1) 2009 in intensive care units in Ireland. Crit Care Resusc. 2010;12:255-261.

106.

Nin

Lorente

Soto

, et al. Acute kidney injury in critically ill patients with 2009 influenza A (H1N1) viral pneumonia: an observational study. Intensive Care Med. 2011;37:768-774. doi:10.1007/s00134-011-2167-7.

107.

Pettilä

Webb

SAR

Bailey

, et al. Acute kidney injury in patients with influenza A (H1N1) 2009. Intensive Care Med. 2011;37:763-767. doi:10.1007/s00134-011-2166-8.

108.

Samra

Pawar

Yadav

Comparative evaluation of acute respiratory distress syndrome in patients with and without H1N1 infection at a tertiary care referral center. Indian J Anaesth. 2011;55:47-51. doi:10.4103/0019-5049.76602.

109.

Tang

Wang

, et al. Comparison of hospitalized patients with ARDS caused by covid-19 and H1N1. Chest. 2020;158(1):195-205.

110.

Tignanelli

Wiktor

Vatsaas

, et al. Outcomes of acute kidney injury in patients with severe ARDS due to influenza A (H1N1) pdm09 virus. Am J Crit Care. 2018;27:67-73.

111.

Trimarchi

Greloni

Campolo-Girard

, et al. H1N1 infection and the kidney in critically ill patients. J Nephrol. 2010;23:725-731.

112.

Vallejos

Arias

Cusumano

, et al. Dialysis for acute kidney injury associated with influenza A (H1N1) infection. Saudi J Kidney Dis Transpl. 2013;24:527-533.

113.

Venkata

Sampathkumar

Afessa

Hospitalized patients with 2009 H1N1 influenza infection: the Mayo Clinic experience. Mayo Clin Proc 2010;85:798-805.

114.

Wang

Chen

, et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis. 2013;57(10):1449-1457. doi:10.1093/cid/cit541.

115.

Arabi

Arifi

Balkhy

, et al. Clinical course and outcomes of critically ill patients with middle east respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160:389-397. doi:10.7326/m13-2486 %m 24474051.

116.

Arabi

Al-Omari

Mandourah

, et al. Critically ill patients with the middle east respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med. 2017;45:1683-1695. doi:10.1097/CCM.0000000000002621.

117.

Dovč

Premru

Pečavar

, et al. Acute kidney injury in critically-ill adult patients with seasonal influenza infection. Clin Nephrol. 2017;88:18-21. doi:10.5414/cnp88fx05.

118.

Diao

Feng

Wang

, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MedRxiv 2020.

119.

Puelles

Lütgehetmann

Lindenmeyer

, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383:590-592. doi:10.1056/NEJMc2011400.

120.

Yang

Wan

, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98:219-227. doi:10.1016/j.kint.2020.04.003.

121.

Miller

Brealey

JK.

Visualization of putative coronavirus in kidney. Kidney Int. 2020;98:231-232. doi:10.1016/j.kint.2020.05.004.

122.

Ding

Zhang

, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004;203(2):622-630. doi:10.1002/path.1560.

123.

Alsaad

Hajeer

Al Balwi

, et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection: clinicopathological and ultrastructural study. Histopathology. 2018;72(3):516-524. doi:10.1111/his.13379.

124.

Carmona

Carlotti

Ramalho

Costa

Ramalho

FS.

Evidence of renal infection in fatal cases of 2009 pandemic influenza A (H1N1). Am J Clin Pathol. 2011;136(3):416-423. doi:10.1309/AJCP1Y6LLHWSKYHW.

125.

Santoriello

Khairallah

Bomback

, et al. Postmortem kidney pathology findings in patients with COVID-19. J Am Soc Nephrol. 2020;31:2158-2167. doi:10.1681/ASN.2020050744.

126.

Chu

Tsang

Tang

, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int. 2005;67:698-705. doi:10.1111/j.1523-1755.2005.67130.x.

127.

Kaddourah

Basu

Bagshaw

, et al. Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med. 2016;376:11-20. doi:10.1056/NEJMoa1611391.

128.

Zhou

Xue

, et al. Coronavirus-associated kidney outcomes in COVID-19, SARS, and MERS: a meta-analysis and systematic review. Ren Fail. 2020;43:1-15. doi:10.1080/0886022x.2020.1847724.

129.

Chen

Y-T

Shao

S-C

Lai

EC-C

, et al. Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis. Critic Care. 2020;24:439. doi:10.1186/s13054-020-03134-8.

130.

Peng

Wang

Sun

, et al. Early versus late acute kidney injury among patients with COVID-19-a multicenter study from Wuhan, China. Nephrol Dial Transplant. 2020;35:2095-2102. doi:10.1093/ndt/gfaa288.

131.

Janse

de Jong

, et al. Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. Clin Kidney J. 2020;13:550-563. doi:10.1093/ckj/sfaa160.

132.

Gomez

Ince

De Backer

, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41:3-11. doi:10.1097/SHK.0000000000000052.

133.

Murugan

Karajala-Subramanyam

Lee

, et al. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010;77:527-535. doi:10.1038/ki.2009.502.

134.

Vaduganathan

Vardeny

Michel

, et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653-1659. doi:10.1056/NEJMsr2005760.

135.

Zarbock

Gomez

Kellum

JA.

Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care. 2014;20:588-595. doi:10.1097/MCC.0000000000000153.

136.

Bellomo

Kellum

Ronco

, et al. Acute kidney injury in sepsis. Intens Care Med. 2017;43:816-828. doi:10.1007/s00134-017-4755-7.

137.

Silver

Beaubien-Souligny

Shah

, et al. The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis. Kidney Med. 2021;3(1):83-98. doi:10.1016/j.xkme.2020.11.008.

138.

Hsu

C-Y.

The role of acute kidney injury in chronic kidney disease. Semin Nephrol. 2016;36:283-292. doi:10.1016/j.semnephrol.2016.05.005.

139.

Lopes

Macedo

AVS

de Barros

Silva

PGM

, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325(3):254-264. doi:10.1001/jama.2020.25864.

140.

Cohen

Hanff

William

, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275-284. doi:10.1016/S2213-2600(20)30558-0.

141.

Bauchner

Golub

Zylke

Editorial concern-possible reporting of the same patients with COVID-19 in different reports. JAMA. 2020;323:1256. doi:10.1001/jama.2020.3980.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.37 MB